| Literature DB >> 20944577 |
Abstract
Replete with investor funds, the Cambridge, Massachusetts–based epigenetics firm is taking aim at methylases anddemethylases linked to disease.Mesh:
Substances:
Year: 2010 PMID: 20944577 DOI: 10.1038/nbt1010-997
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908